We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

U.S. LIPOSOMAL DOXORUBICIN MARKET ANALYSIS

U.S. Liposomal Doxorubicin Market, by Drug Type (Branded and Generic), by Cancer Type (Ovarian Cancer, AIDS-related Kaposi’s Sarcoma, Multiple Myeloma, and Others), and by States (California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, New Jersey, Virginia, Washington, Arizona, and Others) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

  • Published In : Jul 2021
  • Code : CMI4508
  • Pages :148
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

Liposomal doxorubicin is a chemotherapy drug, which is administered intravenously to treat AIDS-related Kaposi's sarcoma, breast cancer, ovarian cancer, and other solid tumors. Liposome drug delivery systems are able to modify pharmacokinetics and bio-distribution of cytostatic agents, it increases the concentration of the drug released to neoplastic tissue and reduces the exposure of normal tissue with the drug. This drug is a type of anthracycline antitumor antibiotic, also known as Doxil and doxorubicin hydrochloride liposome. Dosage of doxorubicin hydrochloride liposome depends on several factors including, height and weight, general health or other health problems, and the type of cancer such as ovarian cancer, AIDS-related kaposi's sarcoma, and multiple myeloma.

The U.S. liposomal doxorubicin market is estimated to be valued at US$ 140.0 Million in 2020 and is expected to reach US$ 192.9 Million by 2027, exhibiting a CAGR of 4.7% over the forecast period (2020-2027).

Figure 1. U.S. Liposomal Doxorubicin Market Value (US$ Million) Analysis and Forecast and Y-o-Y Growth (%), 2020

U.S. LIPOSOMAL DOXORUBICIN MARKET

To learn more about this report, Request sample copy

The increasing approval of generic products is expected to drive the U.S. liposomal doxorubicin market growth

The increasing approval of generic products of liposomal doxorubicin from regulatory authorities is expected to boost demand for liposomal doxorubicin and this is further expected to drive growth of the U.S. liposomal doxorubicin market. For instance, in March 2017, Dr. Reddy’s Laboratories Ltd announced that it received the U.S. Food Drug and Administration approval to launch doxorubicin hydrochloride liposome injection in the U.S., which is a generic version of Janssen Products’ Doxil (doxorubicin hydrochloride liposome injection). Doxorubicin hydrochloride liposome injection is indicated for the treatment of ovarian cancer and administered intravenously in the patients.

U.S. Liposomal Doxorubicin Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2020: US$ 140.0 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.7% 2027 Value Projection: US$ 192.9 Mn
Geographies covered:
  • U.S.
Segments covered:
  • By Drug Type: Branded, Generic
  • By Cancer Type: Ovarian Cancer, AIDS-related Kaposi’s Sarcoma, Multiple Myeloma, Others
  • By States: California, Texas, Florida, New York, Pennsylvania, Illinois, Ohio, Georgia, North Carolina, Michigan, New Jersey, Virginia, Washington, Arizona, Others
Companies covered:

Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.

Growth Drivers:
  • Increasing prevalence of cancer
  • Increasing approvals of generic products
Restraints & Challenges:
  • Side effects associated with liposomal doxorubicin
  • COVID-19 impact on liposomal doxorubicin retail sales

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Figure 2. U.S. Liposomal Doxorubicin Market Share (%), By Cancer Type 2020

U.S. LIPOSOMAL DOXORUBICIN MARKET

To learn more about this report, Request sample copy

U.S. Liposomal Doxorubicin Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. The private healthcare sector is one of the sectors, which has been majorly impacted by the pandemic. The lockdowns in various countries have created an economic burden on the private healthcare sector. Healthcare providers are facing challenges with regards to manpower, equipment, consumables, and other resources to ensure safety of patients with other diseases, and declining outpatients’ visits, among others. Moreover, the pandemic has negatively impacted the development, production, and supply of drugs, and affected growth of the liposomal doxorubicin market and healthcare segment of various companies across the globe. This has led to closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of products. Thus, the Covid-19 pandemic is expected to slightly disrupt the R&D activities of healthcare sector as well as in the liposomal doxorubicin market.

U.S. Liposomal Doxorubicin Market: Restraint

Some side effects associated with liposomal doxorubicin drug is expected to hamper the growth of market. The side effects include increased risk of infection, breathlessness and pale complexion, bruising, bleeding gums and nosebleeds, tiredness and weakness (fatigue) during and after treatment, redness, soreness, and peeling of the hands and feet, loss of weight, and diarrhea among others.

Key Players

Major players operating in the U.S. liposomal doxorubicin market include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddy’s Laboratories, Inc.

Share

Missing comfort of reading report in your local language? Find your preferred language :

Frequently Asked Questions

The global U.S. Liposomal Doxorubicin Market size was valued at USD 140.0 million in 2020 and is expected to reach USD 192.9 million in 2027.

The U.S. liposomal doxorubicin market is estimated to be valued at US$ 140.0 Million in 2020 and is expected to increase to US$ 192.9 Million by 2027, exhibiting a CAGR of 4.7% over the forecast period.

The increasing prevalence of cancer and increasing approvals of generic liposomal doxorubicin products are expected to drive the market growth over the forecast period.

Generic is the leading drug type segment in the market.

Side effects associated with liposomal doxorubicin and COVID-19 impact on liposomal doxorubicin retail sales are the major factors that are restraining growth of the market.

Major players operating in the market include Johnson & Johnson, Baxter International Inc., Sun Pharmaceutical Industries Ltd., and Dr. Reddys Laboratories, Inc.
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification
Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Select a License Type





Logo

Credibility and Certifications

DUNS Registered

860519526

ESOMAR
Credibility and Certification

9001:2015

Credibility and Certification

27001:2022

Clutch
Credibility and Certification

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.